MA27952A1 - Anticorps neutralisants anti-ngf humains utilises comme inhibiteurs selectifs de la voie de ngf - Google Patents

Anticorps neutralisants anti-ngf humains utilises comme inhibiteurs selectifs de la voie de ngf

Info

Publication number
MA27952A1
MA27952A1 MA28809A MA28809A MA27952A1 MA 27952 A1 MA27952 A1 MA 27952A1 MA 28809 A MA28809 A MA 28809A MA 28809 A MA28809 A MA 28809A MA 27952 A1 MA27952 A1 MA 27952A1
Authority
MA
Morocco
Prior art keywords
ngf
antibodies
neutralizing antibodies
human anti
selective inhibitors
Prior art date
Application number
MA28809A
Other languages
English (en)
Inventor
Kenneth D Wild
James J S Treanor
Haichun Huang
Heather Inoue
Tie J Zhang
Frank Martin
Original Assignee
Amgen Inc
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Medarex Inc filed Critical Amgen Inc
Publication of MA27952A1 publication Critical patent/MA27952A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Cette invention concerne des anticorps qui interagissent avec ou se lient à un facteur de croissance du nerf (NGF) humain et neutralisent la fonction de NGF. Cette invention porte sur des compositions pharmaceutiques de ces anticorps et sur des procédés de neutralisation de la fonction de NGF, notamment pour traiter des troubles liés à NGF (par exemple la douleur chronique) par administration d'une quantité pharmaceutiquement efficace d'anticorps anti-NGF. L'invention porte également sur des procédés de détection de la quantité de NGF dans un échantillon au moyen d'anticorps anti-NGF.
MA28809A 2003-07-15 2006-02-15 Anticorps neutralisants anti-ngf humains utilises comme inhibiteurs selectifs de la voie de ngf MA27952A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48743103P 2003-07-15 2003-07-15

Publications (1)

Publication Number Publication Date
MA27952A1 true MA27952A1 (fr) 2006-06-01

Family

ID=34215825

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28809A MA27952A1 (fr) 2003-07-15 2006-02-15 Anticorps neutralisants anti-ngf humains utilises comme inhibiteurs selectifs de la voie de ngf

Country Status (30)

Country Link
US (7) US7601818B2 (fr)
EP (2) EP1648509B8 (fr)
JP (8) JP4489077B2 (fr)
CN (3) CN1849138B (fr)
AR (2) AR045056A1 (fr)
AU (2) AU2004267030B2 (fr)
BR (1) BRPI0412567B1 (fr)
CA (1) CA2534585C (fr)
CY (1) CY1113167T1 (fr)
DK (1) DK1648509T3 (fr)
EA (2) EA030259B8 (fr)
ES (1) ES2392954T3 (fr)
GE (4) GEP20196963B (fr)
HR (2) HRP20120882T1 (fr)
IL (5) IL173076A (fr)
MA (1) MA27952A1 (fr)
ME (2) ME02785B (fr)
MX (2) MX341869B (fr)
NO (1) NO20060381L (fr)
NZ (3) NZ599196A (fr)
PL (1) PL1648509T3 (fr)
PT (1) PT1648509E (fr)
RS (2) RS20100555A (fr)
SG (1) SG10201404744RA (fr)
SI (1) SI1648509T1 (fr)
TN (1) TNSN06010A1 (fr)
TW (4) TWI635096B (fr)
UA (2) UA97086C2 (fr)
WO (1) WO2005019266A2 (fr)
ZA (1) ZA200600847B (fr)

Families Citing this family (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2004032870A2 (fr) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Procedes de traitement d'une douleur post-chirurgicale par administration d'un antagoniste du facteur de croissance neuronal, et compositions renfermant celui-ci
US7255860B2 (en) * 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
DK1575517T3 (da) * 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
UA97086C2 (uk) * 2003-07-15 2012-01-10 Емджен, Інк. Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf)
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
KR101637908B1 (ko) 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
US9396212B2 (en) 2004-04-07 2016-07-19 Visible World, Inc. System and method for enhanced video selection
US7725178B2 (en) * 2004-06-30 2010-05-25 Cedars-Sinai Medical Center Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges
ME00226B (me) * 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
TWI306862B (en) * 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
JP5096167B2 (ja) 2005-01-24 2012-12-12 メドイミューン リミテッド Ｎｇｆに対する特異的結合メンバー
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
CA2615731A1 (fr) * 2005-07-29 2007-02-08 Amgen Inc. Formulations inhibant l'agregation de proteines
WO2007051477A2 (fr) * 2005-11-07 2007-05-10 Copenhagen University Sequences peptidiques derivees de la neurotrophine
US7822474B2 (en) * 2005-11-30 2010-10-26 Cedars-Sinai Medical Center Methods for the prediction of arrhythmias and prevention of sudden cardiac death
EP2076285A4 (fr) * 2006-10-19 2010-06-30 Merck Sharp & Dohme Antagonistes d'anticorps du récepteur 1 de l'interleukine-13
MX2009005189A (es) 2006-11-15 2009-06-30 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso.
EP2129401B8 (fr) * 2006-12-21 2020-01-15 Amgen Inc. Formulations tamponnées stables contenant des polypeptides
JP5675109B2 (ja) * 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
AU2012216653B2 (en) * 2007-08-10 2013-12-12 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
PL2187964T3 (pl) * 2007-08-10 2015-03-31 Regeneron Pharma Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu
AU2008293425B2 (en) * 2007-08-31 2014-09-18 Amgen Inc. Solid-state protein formulation
AU2008304111B2 (en) * 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
JP5737944B2 (ja) 2007-12-17 2015-06-17 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 間質性膀胱炎の治療
JP2011520898A (ja) 2008-05-13 2011-07-21 ノビミューン エスアー 抗ｉｌ−６／ｉｌ−６ｒ抗体およびそれらの使用方法
WO2009150623A1 (fr) 2008-06-13 2009-12-17 Pfizer Inc Traitement de la prostatite chronique
KR20110039218A (ko) * 2008-06-30 2011-04-15 노보 노르디스크 에이/에스 항－인간 인터루킨－２０ 항체
SI2331090T1 (en) * 2008-09-19 2018-04-30 Pfizer Inc. Stable liquid antibody formulation
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
RU2016116516A (ru) 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
ES2514319T3 (es) 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
WO2010146511A1 (fr) 2009-06-17 2010-12-23 Pfizer Limited Traitement d'une vessie hyperactive
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
US10471212B2 (en) * 2009-10-29 2019-11-12 W. L. Gore & Associates, Inc. Silicone free drug delivery devices
US9597458B2 (en) 2009-10-29 2017-03-21 W. L. Gore & Associates, Inc. Fluoropolymer barrier materials for containers
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
KR20130031247A (ko) 2010-03-17 2013-03-28 애보트 리서치 비.브이. 항―신경 성장 인자（ｎｇｆ） 항체 조성물
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
ES2545411T5 (es) 2010-06-07 2024-04-05 Amgen Inc Dispositivo de administración de fármaco
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
US11612697B2 (en) 2010-10-29 2023-03-28 W. L. Gore & Associates, Inc. Non-fluoropolymer tie layer and fluoropolymer barrier layer
US9783601B2 (en) * 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
WO2012135315A1 (fr) 2011-03-31 2012-10-04 Amgen Inc. Adaptateur de flacon et système
LT2699293T (lt) 2011-04-20 2019-04-25 Amgen Inc. Automatinio purškimo prietaisas
US9102673B2 (en) 2011-07-12 2015-08-11 Merck Sharp & Dohme Corp. Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors
RS56876B1 (sr) 2011-08-11 2018-04-30 Astellas Pharma Inc Novo antitelo protiv humanog ngf
EP3045187B1 (fr) 2011-10-14 2019-04-10 Amgen Inc. Injecteur et procédé d'assemblage
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
WO2013176970A1 (fr) 2012-05-22 2013-11-28 Merck Sharp & Dohme Corp. Inhibiteurs de kinase trk-a, compositions et méthodes correspondantes
AR091116A1 (es) 2012-05-22 2015-01-14 Bristol Myers Squibb Co Anticuerpos biespecificos y sus metodos de uso
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP2015535464A (ja) 2012-11-21 2015-12-14 アムジエン・インコーポレーテツド 薬剤送達装置
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
TWI592183B (zh) 2013-03-15 2017-07-21 安美基公司 本體輪廓可調適之自動注射器裝置
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
US10492990B2 (en) 2013-03-15 2019-12-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
WO2014144817A2 (fr) 2013-03-15 2014-09-18 Amgen Inc. Polypeptides inhibiteurs spécifiques à des inhibiteurs wnt
ES2853748T3 (es) 2013-03-22 2021-09-17 Amgen Inc Inyector y método de montaje
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3712166A1 (fr) 2013-09-05 2020-09-23 Amgen Inc. Molécules contenant des fc et présentant des profils de glycoforme prévisibles, uniformes et reproductibles
WO2015039334A1 (fr) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions en contenant et procédés correspondants
WO2015039333A1 (fr) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions en contenant et procédés correspondants
EP3060275B1 (fr) 2013-10-24 2019-07-03 Amgen Inc. Injecteur et procédé d'assemblage
MX2016005315A (es) 2013-10-24 2016-08-11 Amgen Inc Sistema de administracion de farmacos con control sensible a la temperatura.
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
CN109820853B (zh) 2014-02-05 2022-05-10 Vm肿瘤药物有限责任公司 取代的杂环化合物在制备治疗癌症药物中的用途
WO2015119906A1 (fr) 2014-02-05 2015-08-13 Amgen Inc. Système d'administration de médicament doté d'un générateur de champ électromagnétique
WO2015143653A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015143652A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015143654A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
SG11201609219QA (en) 2014-05-07 2016-12-29 Amgen Inc Autoinjector with shock reducing elements
WO2015175861A1 (fr) 2014-05-16 2015-11-19 Amgen Inc. Dosage pour la détection de populations de cellules th1 et th2
US20170103186A1 (en) 2014-06-03 2017-04-13 Amgen Inc. Systems and methods for supporting patient use of a drug delivery device
WO2016035052A1 (fr) * 2014-09-05 2016-03-10 Nvip Pty Ltd Anticorps anti-facteur de croissance nerveuse pour traiter le prurit
ES3056224T3 (en) 2014-10-14 2026-02-19 Amgen Inc Drug injection device with visual and audible indicators
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
EP3689394A1 (fr) 2014-12-19 2020-08-05 Amgen Inc. Dispositif d'administration de médicaments avec bouton mobile ou panneau d'interface utilisateur
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN104910274B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株
CN104774265B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株
US10583245B2 (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
WO2016146730A1 (fr) * 2015-03-19 2016-09-22 Neuheart S.R.L. Peptides ayant une activité agoniste du récepteur trka ou une activité antagoniste du ngf
MA41842A (fr) 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope
WO2016161572A1 (fr) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et procédés associés
WO2016190263A1 (fr) 2015-05-22 2016-12-01 アステラス製薬株式会社 NOUVEAU FRAGMENT Fab D'ANTICORPS CONTRE LE NGF HUMAIN
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
ES2964640T3 (es) 2015-08-13 2024-04-08 Amgen Inc Filtración en profundidad cargada de proteínas de unión al antígeno
CA2995109A1 (fr) * 2015-08-13 2017-02-16 University Of Massachusetts Anticorps humains diriges contre la rage et utilisations de ces derniers
WO2017039786A1 (fr) 2015-09-02 2017-03-09 Amgen Inc. Adaptateur d'ensemble de seringue pour une seringue
EP3368039A1 (fr) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Mutations ponctuelles dans le cancer résistant aux inhibiteurs de trk et méthodes associées
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
WO2017120178A1 (fr) 2016-01-06 2017-07-13 Amgen Inc. Auto-injecteur pourvu d'une électronique de signalisation
JP2019505520A (ja) * 2016-01-13 2019-02-28 ゲンマブ エー／エス 抗体およびその薬物コンジュゲートの製剤
US10053515B2 (en) 2016-01-22 2018-08-21 Merck Sharp & Dohme Corp. Anti-coagulation factor XI antibodies
JP7014724B2 (ja) 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Ｆａｂ免疫グロブリンおよびその使用
WO2017160799A1 (fr) 2016-03-15 2017-09-21 Amgen Inc. Réduction de la probabilité de casse du verre dans des dispositifs d'administration de médicament
UA125026C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ
UA125025C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. Способи лікування дитячих ракових захворювань
WO2017189089A1 (fr) 2016-04-29 2017-11-02 Amgen Inc. Dispositif d'administration de médicament avec étiquette de messagerie
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
WO2017200989A1 (fr) 2016-05-16 2017-11-23 Amgen Inc. Chiffrement de données dans des dispositifs médicaux à capacité de calcul limitée
MX392604B (es) 2016-05-18 2025-03-24 Array Biopharma Inc Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo.
ES3066292T3 (en) 2016-06-03 2026-05-12 Amgen Inc Impact testing apparatuses and methods for drug delivery devices
EA201892716A1 (ru) 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Антитела к фактору свертывания xi
EP3478342B1 (fr) 2016-07-01 2025-03-12 Amgen Inc. Dispositif d'administration de médicament présentant un risque réduit au minimum de fracture de composant lors d'événements d'impact
BR112019002039A2 (pt) 2016-08-05 2019-05-07 Medimmune, Llc anticorpos anti-o2 e uso dos mesmos
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
GB201614884D0 (en) * 2016-09-01 2016-10-19 Oblique Therapeutics Ab Method
GB201617002D0 (en) 2016-10-06 2016-11-23 Oblique Therapeutics Ab Multi-protease method
CA3039686A1 (fr) 2016-10-19 2018-04-26 Medimmune, Llc Anticorps anti-o1 et leurs utilisations
EP3532127B1 (fr) 2016-10-25 2026-04-08 Amgen Inc. Injecteur de contact de corps
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
GB201621907D0 (en) * 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
WO2018136398A1 (fr) 2017-01-17 2018-07-26 Amgen Inc. Dispositifs d'injection et procédés d'utilisation et d'assemblage associés
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
AU2018220538B2 (en) 2017-02-17 2023-12-14 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
WO2018165143A1 (fr) 2017-03-06 2018-09-13 Amgen Inc. Dispositif d'administration de médicaments doté d'une fonction de prévention d'activation
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
SG11201908062QA (en) 2017-03-09 2019-09-27 Amgen Inc Insertion mechanism for drug delivery device
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
MX2019011416A (es) 2017-03-28 2019-11-01 Amgen Inc Sistema y metodo para conjunto de jeringa y vastago de embolo.
CA3066399A1 (fr) 2017-06-08 2018-12-13 Amgen Inc. Dispositif d'administration de medicament entraine par couple
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
JP7475860B2 (ja) 2017-06-23 2024-04-30 アムジエン・インコーポレーテツド スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
JP7408398B2 (ja) 2017-07-14 2024-01-05 アムジエン・インコーポレーテツド 二重ねじりばねシステムを有する針挿入後退システム
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
EP3658206A1 (fr) 2017-07-25 2020-06-03 Amgen Inc. Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
WO2019022951A1 (fr) 2017-07-25 2019-01-31 Amgen Inc. Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
US12318593B2 (en) 2017-08-09 2025-06-03 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567B1 (fr) 2017-08-18 2026-02-18 Amgen Inc. Injecteur portable avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (fr) 2017-10-04 2023-02-08 Amgen Inc. Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
EP4257164A3 (fr) 2017-10-06 2024-01-17 Amgen Inc. Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
ES3069718T3 (en) 2017-11-03 2026-06-10 Amgen Inc System and approaches for sterilizing a drug delivery device
CA3079197A1 (fr) 2017-11-06 2019-05-09 Amgen Inc. Dispositif d'administration de medicament avec detection de positionnement et de debit
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
JP7747438B2 (ja) 2017-11-16 2025-10-01 アムジエン・インコーポレーテツド 失速及び終点検出を有するオートインジェクタ
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
EP3765516A2 (fr) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Molécules multifonctionnelles et utilisations associées
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
CN108623687A (zh) 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用
CN112074541A (zh) 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
JPWO2019221097A1 (ja) 2018-05-15 2021-05-27 アステラス製薬株式会社 抗ヒトｎｇｆ抗体又はその抗原結合フラグメントを有効成分とする心房細動の抑制用医薬組成物
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
CA3103682A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration pour l'administration de medicaments
CN112469454B (zh) 2018-07-24 2024-01-26 安进公司 用于施用药物的输送装置
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
CA3106452A1 (fr) 2018-09-24 2020-04-02 Amgen Inc. Systemes et procedes de dosage interventionnel
US12042642B2 (en) 2018-09-28 2024-07-23 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (fr) 2018-10-02 2020-04-09 Amgen Inc. Systèmes d'injection pour administration de médicament avec transmission de force interne
JP7547325B2 (ja) 2018-10-05 2024-09-09 アムジエン・インコーポレーテツド 投薬量インジケータを有する薬物送達デバイス
IT201800009384A1 (it) 2018-10-11 2020-04-11 Cosmo Srl Peptide for cosmetic application
JP7719714B2 (ja) 2018-10-15 2025-08-06 アムジエン・インコーポレーテツド ダンピング機構を有する薬物送達装置
MA53913A (fr) 2018-10-15 2022-01-19 Amgen Inc Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
WO2020091956A1 (fr) 2018-11-01 2020-05-07 Amgen Inc. Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
EP3958934B1 (fr) 2019-04-24 2025-04-09 Amgen Inc. Ensembles et procédés de vérification de stérilisation de seringue
US20220273887A1 (en) 2019-08-23 2022-09-01 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
EP4045515A4 (fr) 2019-10-18 2023-10-18 The Regents Of The University Of Michigan Systèmes de capteurs pour biomatériaux
CN117050175B (zh) * 2020-04-17 2024-07-16 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN117186219B (zh) * 2020-04-17 2024-07-12 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
WO2021238886A1 (fr) 2020-05-27 2021-12-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Anticorps reconnaissant de manière spécifique le facteur de croissance nerveuse et leurs utilisations
TW202210467A (zh) 2020-05-28 2022-03-16 美商美國禮來大藥廠 TrkA抑制劑
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
WO2021247892A1 (fr) 2020-06-04 2021-12-09 Amgen Inc. Évaluation de procédures de nettoyage d'un procédé de fabrication biothérapeutique
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Dartsbio Pharmaceuticals Ltd. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
BR112023024278A2 (pt) 2021-05-21 2024-01-30 Amgen Inc Método de otimizar uma receita de enchimento para um recipiente de fármacos
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
MX2024007088A (es) 2021-12-16 2024-08-22 Intervet Int Bv Anticuerpos caninizados contra el ngf humano.
US20240002491A1 (en) 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
JP2026516670A (ja) 2023-04-20 2026-05-26 アムジエン・インコーポレーテツド 相対的な不対グリカン含有量を決定する方法
FR3148027A1 (fr) * 2023-04-24 2024-10-25 Peptinov Composition vaccinale anti-ngf
AU2024325342A1 (en) 2023-08-14 2026-02-26 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (fr) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
WO2025264860A2 (fr) 2024-06-18 2025-12-26 Yale University Méthodes de traitement d'une maladie des voies respiratoires post-covid
WO2026030152A1 (fr) 2024-07-29 2026-02-05 Amgen Inc. Système et procédé d'évaluation de la transférabilité d'une recette de remplissage
WO2026090253A1 (fr) 2024-10-23 2026-04-30 Amgen Inc. Procédés de détermination de la teneur en appariement de glycanes
WO2026111937A2 (fr) 2024-11-25 2026-05-28 Eli Lilly And Company Agents interférants d'arn de trka et leurs utilisations
CN121410259B (zh) * 2025-12-30 2026-03-20 北京索莱宝科技有限公司 用于检测人β-NGF含量的双抗夹心ELISA试剂盒

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230691A (en) * 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
GB2077573A (en) 1980-06-10 1981-12-23 Kangol Magnet Ltd Vehicle seat belt connection device
US4786593A (en) * 1985-04-16 1988-11-22 Wistar Institute Of Anatomy And Biology Diagnostic method for detection of neural crest disease
JP2969647B2 (ja) 1988-09-14 1999-11-02 東ソー株式会社 モノクローナル抗体、それからなる阻害剤及びそれを用いた測定方法
SE465573B (sv) 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
US5656435A (en) * 1989-08-28 1997-08-12 Takeda Chemical Industries, Ltd. Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof
EP0418590B1 (fr) 1989-08-28 1997-11-19 Takeda Chemical Industries, Ltd. Anticorps, leur production et utilisation
JPH03163095A (ja) 1989-08-28 1991-07-15 Takeda Chem Ind Ltd ヒト神経成長因子の部分ペプチド、抗体およびその用途
JP3232415B2 (ja) 1990-08-29 2001-11-26 武田薬品工業株式会社 モノクローナル抗体，その製造法および用途
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
JPH06317587A (ja) 1990-08-31 1994-11-15 Takeda Chem Ind Ltd 抗体およびその用途
US5147294A (en) * 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
JPH0576384A (ja) 1991-09-20 1993-03-30 Hitachi Ltd 抗ヒト神経成長因子モノクローナル抗体
JP3519096B2 (ja) 1992-07-02 2004-04-12 武田薬品工業株式会社 モノクローナル抗体、ハイブリドーマおよびそれらの用途
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
CA2219361C (fr) 1995-04-27 2012-02-28 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
GB9616105D0 (en) * 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
US7322122B2 (en) 1997-01-15 2008-01-29 Draka Comteq B.V. Method and apparatus for curing a fiber having at least two fiber coating curing stages
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
EP2110138A1 (fr) * 1999-08-27 2009-10-21 Genentech, Inc. Dosages pour le traitement des anticorps anti-erbB2
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
KR20100132559A (ko) * 2001-05-30 2010-12-17 제넨테크, 인크. 다양한 질환의 치료에 유용한 항-엔지에프 항체
AU2002368077B2 (en) * 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1369431A4 (fr) 2001-10-15 2005-01-12 Kirin Brewery Anticorps anti-hlr-dr
EP1467756A4 (fr) * 2001-12-28 2007-03-21 Abgenix Inc Procedes d'utilisation d'anticorps anti-muc18
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
WO2004032870A2 (fr) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Procedes de traitement d'une douleur post-chirurgicale par administration d'un antagoniste du facteur de croissance neuronal, et compositions renfermant celui-ci
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK1575517T3 (da) * 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
EP1468999A1 (fr) * 2003-03-20 2004-10-20 MyoContract Ltd. Dérivés substitués de la pipéridine et la pipérazine comme modulateurs du récepteur de la melanocortine-4
UA97086C2 (uk) * 2003-07-15 2012-01-10 Емджен, Інк. Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf)
JP5096167B2 (ja) 2005-01-24 2012-12-12 メドイミューン リミテッド Ｎｇｆに対する特異的結合メンバー

Also Published As

Publication number Publication date
US20160237147A1 (en) 2016-08-18
EP1648509B1 (fr) 2012-09-12
EA013614B1 (ru) 2010-06-30
BRPI0412567A (pt) 2006-09-19
CN1849138A (zh) 2006-10-18
IL173076A0 (en) 2006-06-11
RS20060022A (en) 2008-06-05
EP1648509A2 (fr) 2006-04-26
JP2015042670A (ja) 2015-03-05
IL241874A0 (en) 2015-11-30
CY1113167T1 (el) 2016-04-13
UA97086C2 (uk) 2012-01-10
TWI385180B (zh) 2013-02-11
EA201000245A1 (ru) 2010-12-30
JP5264798B2 (ja) 2013-08-14
JP5965964B2 (ja) 2016-08-10
GEP20196963B (en) 2019-04-10
TW201311721A (zh) 2013-03-16
JP2010006812A (ja) 2010-01-14
US8106167B2 (en) 2012-01-31
PT1648509E (pt) 2012-10-18
SG10201404744RA (en) 2014-10-30
HRP20120882T1 (hr) 2013-02-28
US8198410B2 (en) 2012-06-12
IL173076A (en) 2015-10-29
TW200911833A (en) 2009-03-16
PL1648509T3 (pl) 2013-02-28
IL214281A (en) 2016-07-31
TWI635096B (zh) 2018-09-11
TWI503328B (zh) 2015-10-11
AR045056A1 (es) 2005-10-12
RS20100555A (sr) 2011-08-31
DK1648509T3 (da) 2013-01-07
JP2012250986A (ja) 2012-12-20
JP2015155413A (ja) 2015-08-27
HRP20060033A2 (en) 2007-04-30
IL206823A0 (en) 2011-08-01
US20090155274A1 (en) 2009-06-18
UA115960C2 (uk) 2018-01-25
TWI382031B (zh) 2013-01-11
HK1088534A1 (en) 2006-11-10
JP2017079782A (ja) 2017-05-18
CN102358903B (zh) 2017-04-26
CN102408483B (zh) 2016-06-08
JP2012161316A (ja) 2012-08-30
CN102358903A (zh) 2012-02-22
MX341869B (es) 2016-09-06
CN1849138B (zh) 2011-11-30
US20080033157A1 (en) 2008-02-07
RS52332B (sr) 2012-12-31
NO20060381L (no) 2006-03-22
JP2010162028A (ja) 2010-07-29
SI1648509T1 (sl) 2012-12-31
AR075790A2 (es) 2011-04-27
US20110040076A1 (en) 2011-02-17
US7601818B2 (en) 2009-10-13
AU2010202177A1 (en) 2010-06-17
MEP31508A (hr) 2010-10-10
ME02785B (fr) 2012-12-31
AU2004267030A1 (en) 2005-03-03
AU2010202177B2 (en) 2013-12-12
TW200513468A (en) 2005-04-16
NZ588527A (en) 2012-06-29
TNSN06010A1 (en) 2007-10-03
EA030259B1 (ru) 2018-07-31
WO2005019266A2 (fr) 2005-03-03
AU2004267030B2 (en) 2010-06-17
HK1096310A1 (en) 2007-06-01
EA030259B8 (ru) 2018-09-28
HRP20060033B1 (hr) 2014-02-28
JP2007537703A (ja) 2007-12-27
US20050074821A1 (en) 2005-04-07
CA2534585C (fr) 2012-02-21
IL214281A0 (en) 2011-08-31
ES2392954T3 (es) 2012-12-17
EA200600254A1 (ru) 2006-12-29
WO2005019266A3 (fr) 2005-04-28
EP2364728A1 (fr) 2011-09-14
IL214280A0 (en) 2011-08-31
NZ544751A (en) 2009-05-31
GEAP201811194A (en) 2018-10-10
CN102408483A (zh) 2012-04-11
CA2534585A1 (fr) 2005-03-03
ZA200600847B (en) 2007-01-31
JP4489077B2 (ja) 2010-06-23
MXPA06000583A (es) 2006-03-30
TW201534621A (zh) 2015-09-16
US7795413B2 (en) 2010-09-14
EP1648509B8 (fr) 2012-10-24
GEP20146050B (en) 2014-03-10
NZ599196A (en) 2014-01-31
US20110091476A1 (en) 2011-04-21
BRPI0412567B1 (pt) 2017-03-21
GEP20104887B (en) 2010-02-10
US20160304596A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
MA33724B1 (fr) Anticorps neutralisants anti-ngf humain en tant qu'inhibiteurs selectifs de la voie du ngf
WO2005019266A3 (fr) Anticorps neutralisants anti-ngf humains utilises comme inhibiteurs selectifs de la voie de ngf
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
EP1478371A4 (fr) Methodes et produits permettant d'ameliorer des reponses immunitaires a l'aide de compose d'imidazoquinoline
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
WO2005102387A3 (fr) Utilisation therapeutique des anticorps anti-cs1
MA31225B1 (fr) Anticorps neutralisants des cytomegalovirus humains et leur utilisation
MA31821B1 (fr) Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations
WO2004034988A3 (fr) Anticorps humains neutralisants anti-ifn-$g(g) utilises comme inhibiteurs selectifs des voies de ifn-$g(g)
MA29321B1 (fr) Vaccin a base de rotavirus vivant attenue pour administration orale
MA35190B1 (fr) Anticorps anti-angptl3 et utilisations de ceux-ci
MXPA05012011A (es) Uso terapeutico de anticuerpos anti-cs1.
WO2003043583A3 (fr) Traitement des troubles immunologiques au moyen des anticorps anti-cd30
DK0804236T3 (da) Anvendelse af anti-TNF-antistoffer som lægemidler til behandling af sygdomme, som involverer forhøjede interleukin-6-serumniveauer
TNSN03058A1 (fr) Derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant.
EP1363666A4 (fr) Methodes de traitement d'etats pathologiques consistant a administrer des quantites faibles d'anticorps
MA31308B1 (fr) Anticorps antisclerostine.
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
WO2008036682A3 (fr) Traitement des troubles hépatiques par l'administration de conjugués de protéine associée au récepteur (rap)
MA32056B1 (fr) Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene
TNSN00139A1 (fr) Acides phenoxyacetiques substitues
WO2003105753A3 (fr) Procedes et compositions pour la greffe de boucles fonctionnelles dans une proteine
WO2004069183A3 (fr) Regulation immunitaire basee sur le ciblage de molecules d'activation precoce
WO2005077122A3 (fr) Composes et compositions convenant comme modulateurs des lxr
BRPI0414688A (pt) tratamento de doença respiratória com anti-receptor de il-2